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Abstract: We describe the case of a 42-year old man who presented with melaena. He was found
to have bleeding varices during endoscopic investigation. Subsequent investigation revealed the
aetiology to be a portal vein thrombosis (PVT) due to an underlying pro-coagulable state (Factor
V Leiden). He was managed with cautious anticoagulation but suffered a life-threatening upper
gastrointestinal bleed that was not amenable to endoscopic treatment or transjugular intrahepatic
portosystemic shunting (TIPS). As such, the only therapeutic option involved the pursuit of surgical
shunt operations. We review the literature regarding this atypical cause of GI-bleeding and discuss
medical and surgical considerations for the management of such patients.
Keywords: Factor V Leiden; Gastrointestinal Hemorrhage; portal vein; portosystemic shunt;
anticoagulation
1. Introduction
Portal vein thrombosis (PVT) is thrombosis of that which develops in the trunk of the portal vein.
It can involve intrahepatic branches of the portal vein due to local hepatic pathology or extra-hepatic
tributaries such as the splenic vein and superior or inferior mesenteric veins [1]. The first case was
described in 1868 [2]. PVT can be a partial or complete occlusion of the main trunk of the portal
vein. The prevalence of PVT in compensated liver disease has been reported to be 0.6–16% [1,3,4].
The management of these can be complex. We report our experience of a patient presenting with severe
pancreatitis who later developed PVT and review the complexities of a case where shunt procedures
cannot easily be performed due to absence of thrombus-free vessels.
2. Case Presentation
A 42-year-old Caucasian gentleman with no significant past medical or family history presented to
the emergency department with epigastric abdominal pain, nausea and vomiting. He was investigated
and found to have acute pancreatitis and was at this stage transferred to Intensive Care for further
management. Subsequent investigations revealed that he had pancreatic necrosis and he was started
on insulin therapy and Creon supplementation.
Two years later, he presented with swelling in the left calf and this was found to have a deep vein
thrombosis (DVT), treated with warfarin anticoagulation for 3-months.
A further one-year later, he was admitted with abdominal pain, nausea, and melaena. At the time
he was also found to have a distended abdomen. He underwent oesophagogastroduodenoscopy, which
revealed large oesophageal varices for which band ligation therapy was administered. Computerised
Tomography (CT) scanning of his abdomen scan during this admission revealed a thrombus in the
Reports 2018, 1, 18; doi:10.3390/reports1030018 www.mdpi.com/journal/reports
Reports 2018, 1, 18 2 of 5
mesenteric vein and portal vein as well as an oedematous colon (Figure 1) and a non-cirrhotic liver.
Thrombophilia blood test screening revealed him to be heterozygous for Factor V Leiden deficiency.


Figure 1. CT image showing an occluded portal vein and the presence of numerous collateral
vessels (varices).
He was treated with the non-selective B-blocker propranolol to reduce portal pressures [5].
He continued to have regular surveillance endoscopies. Subsequently, aspirin therapy was commenced
by the haematology team to reduce the risk of further thrombus formation whilst balancing the risk of
bleeding. Later that year, he was admitted with left leg swelling and a DVT was confirmed and he was
restarted on warfarin.
Four months later, he was admitted with significant haematemesis, vomiting approximately 1.5 L
of blood. He was haemodynamically unstable and thus intubated and managed in Intensive Care with
a blood transfusion, Sengstaken-Blakemore tube, the vasopressin analogue terlipressin and airway
support [5]. Subsequent endoscopy revealed bleeding gastric fundal varices that did not respond to
endoscopic sclerotherapy with cyanoacrylate injection [5].
A CT scan showed further extension of the thrombus (Figure 2) and, after discussion with a
quaternary centre, the Sengstaken Blakemore was maintained until the patient could undergo a surgical
shunt. Anatomical considerations (thrombus in the portal, splenic and mesenteric veins) made this
technically difficult and following initial stabilisation, splenectomy with oesophageal devascularisation
was considered the best alternative treatment. The patient suffered a further massive haemorrhage
and, despite resuscitative efforts, died from bleeding before they could perform the procedure.
Ethics and Consent: Consent was gained directly from the patient’s next of kin. As per
Abertawe Bro Morganwwg University Health Board Research and Development (ABMU R&D) policy,
no additional ethical approval was required.
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Figure 2. CT image showing extension of thrombus into the superior mesenteric vein (SMV) adjacent
to the superior mesenteric artery (SMA).
3. Discussion
PVT has a multitude of causes summarised in Table 1 [6]. The commonest cause is secondary to
cirrhosis, but non-cirrhotic extrahepatic PVT presentation is quite variable (due to vague symptom
onset). Bleeding due to portal hypertension and the development of oesophageal varices is seen in up
to 30% of such cases [7].
Table 1. Summarising the pathogenesis and aetiology of PVT.
Pathogenesis Aetiology
Idiopathic
Local inflammation
Local inflammation including:
- Pancreatitis
- Cholecystitis
- Liver abscess
Fibrosis/Malignancy:
- Cirrhosis
- Hepatocellular cancer
- Pancreatic cancer
Local trauma/injury
(Direct damage to portal vein)
- Abdominal trauma
- Surgery (e.g., laparoscopic surgery), splenectomy
- Radiological interventions such as radiofrequency ablation for hepatocellular cancer
Prothrombotic disorders
Inherited:
- Factor V Leiden
- Protein C/S deficiency
Acquired:
- Myeloproliferative disorders
- Anti-phosphospholipid syndrome
- Drug induced thrombosis (e.g., oral contraceptive pill)
Physiological Pregnancy
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Managing these patients is difficult and dependent on chronicity of thrombus. The differentiation
between acute and chronic PVT is aided by CT-evidence of portal collaterals, splenomegaly,
or oesophageal varices.
Anticoagulation should ideally be initiated within the first month of symptoms to allow early
decompression of the portal system and reduce the risk of variceal development and bleeding.
Recanalisation decreases from 69% in the first week to 25% in the second [8]. Recanalisation is less
likely if extensive thrombosis or underlying prothrombotic disorder [9]. Most portal veins recanalise
between 4–6 months and, therefore, patients should remain on anticoagulation for 6-months [10,11].
Long-term anticoagulation may be recommended for those with recurrent thrombosis, family
history, or underlying prothrombotic disorders. Whilst controversial, anticoagulation does not appear
to increase the risk or severity of bleeding in patients with known varices, although a more cautious
approach should be considered if varices are large—the only significant predictor for bleeding [6].
Active variceal patients should be treated endoscopically in the first instance, which can produce
spontaneous shunt formation in up to 40% of patients, which, in turn, serves to protect from further
bleeding [6]. Whilst transjugular intrahepatic portosystemic shunt (TIPS) is sometimes useful to
manage difficult to control bleeding, its efficacy is questionable in cannulating blocked portal veins.
If these approaches fail, then the patient usually requires specialist input and bypass (shunt)
surgery. Numerous shunt options can be considered, being cognisant of patency of vessels. As such,
particularly in patients with thrombus extending into the mesenteric vessels, management can
be challenging, summarised in Table 2 [6,12]. Furthermore, given the rarity of presentation with
non-cirrhotic portal venous occlusion with no vascular access to benefit from TIPS, experience with
such shunt operations is often limited to a few specialist centres.
Table 2. Summary of management options of PVT.
Shunt Option Anatomical Connection Clinical Consideration
Radiological (TIPS) Portal to Hepatic Vein Requires patent portal vein. Rarely effective
Non-selective Portosystemic
Shunt
Inferior Vena Cava
- Mesocaval
- Portocaval
Caution in patients with ascites or
encephalopathy
Right Atrium
- Mesoatrial
- Portoatrial
Useful in bypassing obstructed hepatic vein
or inferior vena cava
Selective Portosystemic
Shunt
Spleno-renal
(Splenic vein to renal vein)
- May include splenectomy
Requires patent splenic vein.
Low risk of encephalopathy
Oesophageal transection±
splenectomy
Extensive thrombosis. Life threatening bleed.
Better outcome in patients without
underlying myeloproliferative disorder
Liver Transplant
Underlying cirrhosis or local damage to PVT.
Consider if conservative measures/shunt
surgery fail
Whilst variceal bleeding is commonly associated with underlying cirrhosis, other aetiologies
such as non-cirrhotic portal vein thrombosis should be considered in the compensated liver
patient. Portal vein thrombosis can affect anywhere between 0.6–16% of such patients, and most
commonly presents with variceal bleeding (30%), although atypical abdominal pain may also be
seen. Recanalisation of the portal vein most commonly occurs in the first week and in association
with reversible conditions such as pancreatitis. Chronic PVT is more commonly associated with
underlying pro-thrombotic states. In the stable, non-bleeding patient, anticoagulation with warfarin
can be considered, even if varices are present. Surgical bypass procedures should be considered in the
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bleeding patient with selection of appropriate shunt procedure guided by CT or MRI angiography to
assess patency of surrounding vessels. In the absence of patent vessels to facilitate such bypass shunts,
splenectomy with or without oesophageal devascularisation can be considered in patients with no
other surgical options who are at risk of exsanguinating. Whilst splenectomy is often reserved for
patients with isolated splenic vein thrombosis, it should be considered at an early stage as a life-saving
salvage approach to patients with bleeding varices from multivessel extrahepatic thrombosis as it can
reduce flow and thereby possibly reduce portal pressures [13].
Author Contributions: J.G.: Developing, proofing the manuscript and editing the images. H.N.H.: Developing,
proofing the manuscript, concept development and editing the images.
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